Arkema Stock: 1.55% Decline Mid-Day, One Week Before Annual Results

Recent Performance and Technical Analysis

Arkema's stock has seen a decrease of 7.56% over the past seven days, correcting a notable increase of nearly 23% over three months. This movement occurs as the stock price now trades above its 50-day and 200-day moving averages, which are at 53.80 euros and 57.36 euros respectively, indicating a still positive underlying momentum despite the recent pullback. However, an RSI at 76 indicates that the stock is in an overbought zone, a level that typically suggests an upward excess likely to lead to short-term profit-taking. The most significant technical resistance is at 65.45 euros, a threshold the price has not managed to surpass during its recent surge. Over a year, the performance remains negative at -27.5%, highlighting the long-term fragile trajectory of the French chemical company.

Upcoming Financial Milestones

The specialty chemicals group will publish its 2025 annual accounts on February 26, exactly one week from now. This date is a crucial moment to assess Arkema's operational trajectory in a sector environment characterized by fluctuations in raw material prices and macroeconomic uncertainties. Beyond this release, the company's financial calendar includes the results for the first quarter of 2026 on May 6, followed by the general meeting scheduled for May 21. The monthly volatility, measured at 14.15%, remains contained for a stock in the chemical sector, while a beta of 0.47 confirms the stock's moderate sensitivity to overall market fluctuations. The approach of these publications calls for a careful review of the fundamentals that the group will communicate in the coming days.